STEMI is increasingly prevalent among a growing population of patients in their nineties, according to a study published in the American Journal of Cardiology Oct. 11.

Using sex-specific thresholds for high-sensitivity cardiac troponin I assays identified five times more heart attacks in women in a recent study of patients with suspected ACS, but major disparities persisted when it came to treating MIs.

The CDC released updated statistics and a new framework for identifying, diagnosing and treating e-cigarette or vaping-related lung disease Oct. 11, putting a name to the recent phenomenon in the process.

Consumer watchdog group U.S. PIRG is criticizing the FDA for “missing their timeline” to review potentially carcinogenic blood pressure medications like losartan, valsartan and irbesartan, arguing the agency needs to step up its efforts to ensure pharmaceutical companies are distributing safe drugs.

An increase in public reporting of aortic valve surgery outcomes has been tied to a decrease in AVR access for patients with infective endocarditis—the unintended consequence of a push for greater transparency in healthcare.

Medtronic on Oct. 7 announced the launch of its EV ICD pivotal study—a prospective, pre-market trial designed to assess the efficacy of an extravascular system in treating dangerous arrhythmias.

Doctors at the University of New Mexico Hospital used an extracorporeal membrane oxygenation system to treat a cardiac arrest patient in the field for the first time last week, the Albuquerque Journal reports.

A study published just two months after the FDA issued a statement acknowledging a late mortality signal with paclitaxel-coated and -eluting stents and balloons suggests the devices are actually safe in patients with lower extremity artery disease.